全文获取类型
收费全文 | 1356篇 |
免费 | 158篇 |
国内免费 | 36篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 60篇 |
妇产科学 | 18篇 |
基础医学 | 146篇 |
口腔科学 | 33篇 |
临床医学 | 149篇 |
内科学 | 340篇 |
皮肤病学 | 63篇 |
神经病学 | 57篇 |
特种医学 | 204篇 |
外科学 | 126篇 |
综合类 | 35篇 |
预防医学 | 112篇 |
眼科学 | 25篇 |
药学 | 115篇 |
肿瘤学 | 61篇 |
出版年
2021年 | 12篇 |
2020年 | 13篇 |
2019年 | 21篇 |
2018年 | 35篇 |
2017年 | 18篇 |
2016年 | 16篇 |
2015年 | 19篇 |
2014年 | 28篇 |
2013年 | 40篇 |
2012年 | 36篇 |
2011年 | 37篇 |
2010年 | 53篇 |
2009年 | 53篇 |
2008年 | 45篇 |
2007年 | 65篇 |
2006年 | 55篇 |
2005年 | 36篇 |
2004年 | 41篇 |
2003年 | 34篇 |
2002年 | 41篇 |
2001年 | 39篇 |
2000年 | 29篇 |
1999年 | 26篇 |
1998年 | 58篇 |
1997年 | 56篇 |
1996年 | 55篇 |
1995年 | 53篇 |
1994年 | 58篇 |
1993年 | 30篇 |
1992年 | 21篇 |
1991年 | 20篇 |
1990年 | 28篇 |
1989年 | 41篇 |
1988年 | 43篇 |
1987年 | 24篇 |
1986年 | 25篇 |
1985年 | 21篇 |
1984年 | 19篇 |
1983年 | 12篇 |
1982年 | 17篇 |
1981年 | 13篇 |
1980年 | 12篇 |
1979年 | 25篇 |
1978年 | 12篇 |
1977年 | 16篇 |
1976年 | 8篇 |
1975年 | 9篇 |
1973年 | 13篇 |
1969年 | 7篇 |
1966年 | 7篇 |
排序方式: 共有1550条查询结果,搜索用时 0 毫秒
101.
102.
103.
H S Greenberg W D Ensminger P B Layton S Gebarski M Meyer B Chaffee J F Bender A J Grillo-Lopez 《Cancer treatment reports》1986,70(3):353-357
Diaziquone (AZQ) is a lypophilic alkylating agent that crosses the blood-brain barrier and has shown broad activity in animal tumor models. Five of 12 patients with malignant astrocytoma treated with iv AZQ had clinical and/or radiographic improvement (Schold, Neurology 34:615, 1984). Intra-arterial administration of AZQ to patients with brain tumors should produce higher peak levels of drug in the tumor and should reduce systemic toxicity. Twenty-one patients with astrocytoma (grade II, four; grade III, 11; and grade IV, six), in all of whom irradiation and intra-arterial carmustine chemotherapy failed, received intra-arterial AZQ as a single dose every 28 days. Two of 20 evaluable patients experienced partial responses of 5 and 8+ months, respectively. Four patients had disease stabilization of 3, 4, 5, and 8 months' duration, respectively, and one of these patients had tumor shrinkage (partial response) after seven courses of AZQ. The initial dose in the first three patients was 10 mg/m2, and doses in subsequent groups of three patients were begun at increases of 5 mg/m2. The within-group dose escalation was 5 mg/m2 per course if there was no hematologic toxicity. Dose-limiting toxicity was myelosuppression, which occurred at doses greater than 15 mg/m2. The maximum tolerated dose was 25 mg/m2. Intra-arterial AZQ appears to be of marginal effectiveness in patients refractory to carmustine and offers no advantage over iv AZQ in efficacy or toxicity. 相似文献
104.
G T Layton P L Devine J A Warren G Birrell P X Xing B G Ward I F McKenzie 《Tumour biology》1990,11(5):274-286
The monoclonal antibody (Mab) OM-1, which defines the ovarian carcinoma-associated sebaceous gland antigen (SGA), and Mab F36/22, which defines the ductal carcinoma antigen (DCA), were tested for reactivity against a synthetic peptide representing the repeat twenty amino acid sequence of the human polymorphic epithelial mucin core protein plus four amino acids of the adjacent sequence (p1-24). OM-1 bound strongly to the peptide by direct dot blot assay and ELISA and the minimum epitope for OM-1 was shown to be APDTRP(A) by inhibition assay. F36/22 reacted weakly with the peptide under the same conditions and its affinity for peptide in solution was relatively very low. Mab OC125, which defines the ovarian cancer-associated antigen CA125, did not react with the p1-24 peptide. Five other anti-mucin Mabs (HMFG1, HMFG2, BC1, BC2, BC3), previously shown to bind to the p1-24 peptide, reacted strongly with SGA by direct binding and in a sandwich assay with OM-1 as the capture Mab. F36/22 was weakly positive under the same conditions suggesting that both peptide and SGA do not express the optimal epitope for F36/22 binding. These results indicate that SGA and possibly DCA have the repeat sequence core protein of the breast carcinoma-associated human polymorphic epithelial mucin. 相似文献
105.
Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia 总被引:7,自引:0,他引:7
We studied 41 patients with myelodysplastic syndromes or acute myeloid leukemia to assess the presence of point mutations in the human FMS gene (M-CSF receptor). Using the polymerase chain reaction and hybridization of oligonucleotide probes to the amplified sequences, we have detected mutations in eight of 41 patients, at codons 301 and 969. In vitro work has highlighted mutations at these codons as being oncogenic. We now report the detection of potentially activating mutations of the human FMS gene in vivo. The consequence of these mutations in the multistep pathogenesis of myeloid malignancy and their relevance to prognosis remains to be determined. 相似文献
106.
Differentiation of Becker muscular dystrophy from limb-girdle muscular dystrophy and Kugelberg-Welander disease using a cDNA probe 总被引:2,自引:0,他引:2
N G Laing M E Mears H E Thomas D C Chandler M G Layton J Goldblatt B A Kakulas 《The Medical journal of Australia》1990,152(5):270-271
A 31-year-old man previously investigated for a neuromuscular disorder was diagnosed as having either limb-girdle dystrophy, spinal muscular atrophy, or Becker muscular dystrophy. Extensive clinical and special neurological investigations failed to clarify this differential diagnosis. However, recent DNA studies have shown a deletion of the dystrophin gene, thereby providing an unequivocal diagnosis of Becker muscular dystrophy. The application of molecular genetic techniques in the diagnosis of inherited neuromuscular disorders is discussed. 相似文献
107.
108.
Summary The myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal disorders arising from a multipotent haemopoietic progenitor which share a leukaemic propensity, 30% of cases culminating in acute myeloid leukaemia (AML). Their pathogenesis probably entails multiple steps, phenotypic progression being determined by either expansion or evolution of the abnormal clone. The clonal origin of certain cases of de novo AML is analogous to that of MDS and evidence that they share a common pathogenesis and distinct biological characteristics is beginning to emerge.D. M. Layton is supported by a grant from the Leukaemia Research Fund. 相似文献
109.
目的探讨医源性脾脏损伤脾切除对结直肠癌切除患者术后长期生存的影响。方法对1990年1月1日至1999年12月31日10年间行结直肠癌手术切除并附带脾切除患者进行病例配对回顾研究。分析患者年龄、性别、依据美国麻醉学医师协会(ASA)标准评估的身体状况、疾病分期、手术类型及预后等资料。配对病例来自同一医疗中心,性别、年龄、疾病分期及手术类型完全相同。手术附带脾切除患者为试验组,未切脾者为对照组。结果55例患者行医源性脾切除术,对照组在年龄、性别、身体状况、疾病分期及手术类型上与之匹配。随访时间(从手术开始到患者死亡或者最后一次随访1为2~205个月(中位随访时间为43个月)。Cox比例危险度模型进行Kaplan-Meier法生存分析发现两组间差异有显著性意义,不切除脾脏对患者生存有利(危险度1.8,95%可信区间为1-3.3,P=0.0399),未切脾组与切脾组5年生存率分别为70%和47%,10年生存率分别为55%和38%。结论结直肠癌患者在行结肠或直肠切除时,因医源性脾脏损伤而切除脾脏者,预后较差。 相似文献
110.
Superparamagnetic iron oxide-enhanced MR imaging: pulse sequence optimization for detection of liver cancer 总被引:3,自引:0,他引:3
Fretz CJ; Elizondo G; Weissleder R; Hahn PF; Stark DD; Ferrucci JT Jr 《Radiology》1989,172(2):393-397
The effects of magnetic resonance (MR) pulse sequences and timing parameters on tumor-liver contrast were studied in an animal model of metastatic liver cancer. Six spin-echo (SE), three inversion-recovery (IR), and four gradient-echo (GRE) sequences were evaluated at 0.6 T before and after injection of super-paramagnetic iron oxide. GRE techniques, irrespective of echo time and flip angle, showed the greatest change in signal intensity (enhancement) of the liver after administration of iron oxide. Single-acquisition GRE sequences (16 seconds) matched the contrast-to-noise ratio (C/N) performance of the most effective 6.4-minute SE sequences. Multiexcitation GRE sequences showed tumor-liver C/Ns per unit time that were significantly (P less than .05) higher than those achieved with SE and IR sequences. GRE sequences, which recruit intravoxel dephasing as an additional source of transverse relaxation enhancement (T2*), show a higher C/N per unit time and in this respect seem superior to SE and IR sequences for MR imaging with superparamagnetic iron oxide. 相似文献